CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Investing.com -- NewLimit, a biotech startup dedicated to extending human lifespan through gene reprogramming, has raised $130 million in a Series B funding round. The funding round, led by venture capital firm Kleiner Perkins, boosts the company’s valuation to $810 million, as reported by Bloomberg, citing a company spokesperson.
NewLimit was founded by Brian Armstrong, the chief executive officer and co-founder of cryptocurrency exchange Coinbase (NASDAQ:COIN) Inc., in 2021. Armstrong has been committed to the development of this technology, which he sees as an underdeveloped field. He has dedicated a portion of the wealth generated from Coinbase’s initial public offering to fund NewLimit.
In addition to his full-time role at Coinbase, Armstrong also serves as an investor and board member of NewLimit. The recent funding round signifies the growing interest in the cutting-edge field of gene reprogramming, aimed at increasing human longevity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.